NCT05019326

Andrographis Paniculata vs Boesenbergia Rotunda vs Control in Asymptomatic COVID-19

A Two-stage Adaptive Randomized Controlled Trial of Andrographis Paniculata Extract, Boesenbergia Rotunda Extract, and Standard Treatment in Asymptomatic COVID-19 Patients

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 3,060 (estimated)
• Sponsor: Mahidol University · Academic / Other
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to examine the effect of Andrographis Extract, Boesenbergia Extract compared to standard treatment in asymptomatic COVID patients.

Conditions

• Covid19

Interventions

Type	Name	Description
DRUG	Andrographis Paniculata	Andrographis extract, equivalent to andrographolide 20 mg per capsule, for a total of 180 mg of andrographolide per day, dosing into 3 capsules taking before meal for 3 times per day, for 5 days.
DRUG	Boesenbergia	Boesenbergia extract, equivalent to pinostrobin 30 mg per capsule, for a total of 180 mg of pinostrobin per day, dosing into 2 capsules taking after meal for 3 times per day for 5 days.
OTHER	Standard supportive treatment	as recommended by guidelines from the Ministry of Public Health, Thailand. No antivirus was given.

Timeline

• Start date: 2021-08-30
• Primary completion: 2022-05-30
• Completion: 2022-05-30
• First posted: 2021-08-24
• Last updated: 2021-09-09

Locations

1 site across 1 country: Thailand